With all the caveats of an observational study, even if the publisher is highly regarded...
A study in JBMR plus found that bone-modifying agents like bisphosphonates and denosumab are linked to improved overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC).
The study analyzed 420 mCRPC patients, with 60% receiving bone-modifying agents.
While no significant differences in progression-free survival were observed, patients who received bone-modifying agents had a significantly longer overall survival (58 months vs. 45 months).
Within the group receiving bone-modifying agents, no significant differences in survival were seen between those on bisphosphonates versus denosumab. The rate of osteonecrosis of the jaw was 12% in both groups. The study suggests that despite low administration rates, these agents offer a meaningful survival benefit in mCRPC patients with bone metastases.